How to think about stacking NAD+
- NAD+ is a coenzyme (molecular weight 663.4, PubChem CID 5892), not a peptide, and on 2026-09-18 DailyMed listed no NAD+ injection. A 2026 systematic review of 113 studies, 33 in humans, concluded that parenteral NAD+ lacks adequate clinical-trial evidence (Gallagher et al., PMID 41655607); no registered trial combines it with a peptide.
- Its concentrations sit in a different range from anything it is stacked with. Vials run from 100 mg to 1,000 mg, so at 1 to 3 mL of water the solution is 33.3 to 1,000 mg/mL; the one registered trial dose, 100 mg in 2 mL (NCT06919328), is 50 mg/mL, where a U-100 unit carries 0.5 mg. A peptide partner at 2.5 to 5 mg/mL carries micrograms per unit, which is the practical reason the two are never measured on the same scale.
- NAD+ is a coenzyme central to cellular energy metabolism, not a receptor-binding peptide. It is supplied rather than signalled, which makes 'mechanism collision' reasoning largely inapplicable.
- Reported administration is uncomfortable at speed — flushing, chest tightness and nausea are commonly reported with rapid delivery, which is why slow administration is emphasised.
- Amounts reported are large relative to peptides, so its figures do not transfer to or from them.
- No controlled trial has studied injectable NAD+ combined with anything, and the evidence base for the injected form specifically is thin.
Combinations in detail
Mitochondrial energy pairing
NAD+ + MOTS-c- Why it is proposed
- Coenzyme supply alongside AMPK signaling — supplying a substrate and activating a pathway are different things, which is the clearest version of this stack's rationale.
- What is reported in practice
- Separate administration; NAD+ reported slowly.
- Cautions specific to this combination
- No combination data. NAD+'s injected-form evidence is the weaker half.
Mitochondrial protection stack
NAD+ + SS-31- Why it is proposed
- Substrate supply alongside cardiolipin-targeted membrane support.
- What is reported in practice
- Separate administration.
- Cautions specific to this combination
- SS-31's clinical record is mixed; combining two mitochondrial approaches does not resolve that.
Cellular-repair longevity stack
NAD+ + Epithalon- Why it is proposed
- Thematic longevity pairing rather than a specified mechanistic interaction.
- What is reported in practice
- Reported in courses following Epithalon's short-course convention.
- Cautions specific to this combination
- Epithalon's literature is concentrated in one research tradition with no controlled human telomere data. The pairing is thematic.
Systemic recovery pairing
NAD+ + BPC-157- Why it is proposed
- Energy-metabolism support alongside tissue-repair signaling; unrelated mechanisms.
- What is reported in practice
- Separate vials and schedules.
- Cautions specific to this combination
- No combination data.
What to avoid, and why
- Rapid administration — reported tolerability problems are dose-rate dependent and are the most consistently reported issue with this compound.
- Carrying NAD+ amounts across to peptide arithmetic; the scales are entirely different.
- Reading NAD+ precursor supplement research as evidence for the injected form.
Related reading
Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.